Arcturus Therapeutics In... (ARCT)

AI Score

Unlock

9.43

-1.16 (-10.95%)

At close: Apr 01, 2025, 3:59 PM

9.80

3.91%

After-hours: Apr 01, 2025, 05:30 PM EDT

-10.95% (1D)

Bid	9.42
Market Cap	255.74M
Revenue (ttm)	139M
Net Income (ttm)	-81.3M
EPS (ttm)	-3
PE Ratio (ttm)	-3.14
Forward PE	-11.04
Analyst	Buy

Ask	9.8
Volume	789,627
Avg. Volume (20D)	412,070
Open	10.49
Previous Close	10.59
Day's Range	9.41 - 10.49
52-Week Range	9.41 - 45.00
Beta	2.96

About ARCT

Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as we...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date May 22, 2013

Employees 174

Stock Exchange NASDAQ

Ticker Symbol ARCT

Website https://arcturusrx.com

Full Company Profile

Analyst Forecast

According to 6 analyst ratings, the average rating for ARCT stock is "Buy." The 12-month stock price forecast is $60, which is an increase of 536.27% from the latest price.

Stock Forecasts

Next Earnings Release

Arcturus Therapeutics Inc. is scheduled to release its earnings on May 7, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

3 weeks ago

-0.5%

Arcturus Therapeutics shares are trading lower aft... Unlock content with Pro Subscription

9 months ago

-25.31%

Arcturus Therapeutics shares are trading lower. The company announced that it presented Phase 1 results in healthy volunteers and Phase 1b interim data in people with CF for ARCT-032 at the 47th European Cystic Fibrosis Conference.

News

3 weeks ago · seekingalpha.com

Arcturus Therapeutics Holdings Inc. (ARCT) Q4 2024 Earnings Call Transcript

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT ) Q4 2024 Earnings Conference Call March 6, 2025 4:30 PM ET Company Participants Neda Safarzadeh - Vice President, Head of Investor Relations Joe Payne...

3 weeks ago · zacks.com

Arcturus Therapeutics (ARCT) Reports Q4 Loss, Misses Revenue Estimates

Arcturus Therapeutics (ARCT) came out with a quarterly loss of $1.11 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.32 per share a year ago.

3 weeks ago · businesswire.com

Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2024 Financial Update and Pipeline Progress

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the developm...

WALTHAM, Mass. & SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Global biotechnology leader CSL (ASX: CSL; USOTC: CSLLY) and sa-mRNA pioneer Arcturus Therapeutics (Nasdaq: ARCT) today announced ...

2 months ago · businesswire.com

Meiji Seika Pharma Receives Approval for Adding Domestic Manufacturing Sites in Japan for KOSTAIVE®, a Self-amplifying mRNA Vaccine Against COVID-19

TOKYO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan, President and Representative Director: Daikichiro Kobayashi) announced today that it has rece...